Histamine in the Treatment of Vertigo

Reference

• Dale H H, Laidlaw PP. The physiological action of β-imidazolylethylamine. J Physiol (Lond) 1910; 41: 318–44
   Google Scholar
• Dale HH. Adventures in physiology. Pergamon Press, London 1953
   Google Scholar
• Grass PM. Cerebral histamine: Indications for neuronal and vescular regulation. J Cereb Blood Flow Metab 1982; 2: 3–23
   PubMed Web of Science ®Google Scholar
• The pharmacological basis of therapeutics., A Goodman Gilman, L S Goodman, A Gilman. Macmillan, New York 1980
   Google Scholar
• Sokoloff L. The action of drugs on the cerebral circulation. Pharmacol Rev 1959; 11: 1–85
   PubMed Web of Science ®Google Scholar
• Mygind S H, Falbe-Hansen J. Experimental histological studies on the Labyrinth IX. Histamine and adrenaline. Acta Otolaryngol (Stockh) 1946; 34: 59–70
   Google Scholar
• Nomura Y. Observations on the microcirculation of the cochlea, an experimental study. Ann Otol 1961; 70: 1037–54
   Google Scholar
• Suga F, Snow JB. Cochlear blood flow in response to vasodilating drugs and some related agents. Laryngoscope 1969; 79: 1956–79
   PubMed Web of Science ®Google Scholar
• Flynn S B, Owen D AA. Histamine receptors in peripheral vascular beds in the cat. Br J Pharmacol 1975; 55: 181–8
   PubMed Web of Science ®Google Scholar
• Arrang J M, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983; 302: 832–7
   PubMed Web of Science ®Google Scholar
• Arrang J M, Garbarg M, Schwartz JC. Autoinhibition of histamine synthesis mediated by presyn-aptic H3 receptors. Neuroscience 1987; 23: 149–57
   PubMed Web of Science ®Google Scholar
• Steinbusch H WM, Mulder AH. Immunohistochemical localization of histamine in neurons and mast cells in the rat brain. Handbook of chemical neuroanatomy. Vol 3. Classical transmitters and transmitter receptors in the CNS., A Björklund, T Hökfelt, MJ Kuhar. Elsevier Science Publishers, Amsterdam 1984; 126–40
   Google Scholar
• Watanabe T, Taguchi Y, Shiosaka S, et al. Distribution of the histaminergic neuron system in the central nervous system of rats: a fluorescent immunohistochemical analysis with histidine decar-boxylase as a marker. Brain Res 1984; 295: 13–25
   PubMed Web of Science ®Google Scholar
• Prell G D, Green JP. Histamine as a neuroregulator. Annu Rev Neurosci 1986; 9: 209–54
   PubMed Web of Science ®Google Scholar
• Kirsten E B, Sharma JN. Microiontophoresis of acetylcholine, histamine and their antagonists on neurones in the medial and lateral vestibular nuclei of the cat. Neuropharmacology 1976; 15: 743–53
   PubMed Web of Science ®Google Scholar
• Gross PM. Multiple actions of histamine on cerebral blood vessels. Adv Biosci 1985; 51: 341–9
   Google Scholar
• Wilson WH. Intravenous and optimum-dosage histamine therapy in Menieres disease. Arch Otolaryngol 1973; 97: 139–41
   PubMedGoogle Scholar
• Norris CH. Drugs affecting the inner ear. Drugs 1988; 36: 754–72
   PubMed Web of Science ®Google Scholar
• Sheldon C H, Horton BT. Treatment of Menieres disease with histamine administered intravenously. Proc Staff Meet Mayo Clin 1940; 15: 17–21
   Google Scholar
• Shambaugh GE. Menieres disease: diagnosis and treatment. Texas J Med 1962; 58: 70–4
   PubMedGoogle Scholar
• Conn HF. Current therapy: Menieres disease, D Jack, MD Clemis, E George, MD. Shambaugh, Jr. WB Saunders Co, Philadelphia 1965
   Google Scholar
• Hicks J J, Hicks J N, Cooley HN. Menieres disease. Arch Otolaryngol 1967; 86: 610–3
   PubMedGoogle Scholar
• Rubin W. Vestibular suppressant drugs. Arch Otolaryngol 1973; 97: 135–8
   PubMedGoogle Scholar
• Bertrand RA. Long-term evaluation of the treatment of Menieres disease with betahistine HCl. Adv Otorhinolaryngol 1982; 28: 104–10
   PubMedGoogle Scholar
• Horton B T, Von Leden H. Clinical use of beta-2-pyridylalkylamines: Part I. Proc Mayo Clin 1962; 37: 692–702
   PubMed Web of Science ®Google Scholar
• Anderson W D, Kubicek WG. Effects of betahistine hydrochloride, nicotinic acid and histamine on basilar blood flow in anaesthetized dogs. Stroke 1971; 2: 409
   PubMed Web of Science ®Google Scholar
• Martinez DM. The effect of Serc (betahistine hydrochloride) on the circulation of the inner ear in experimental animals. Acta Otolaryngol (Stockh) 1972; 305: 29
   Google Scholar
• Tomita M, Gotoh F, Sato T, et al. Comparative responses of the carotid and vertebral arterial systems of rhesus monkeys to betahistine. Stroke 1978; 9: 382–7
   PubMed Web of Science ®Google Scholar
• Unemoto H, Sasa M, Takaori S, Ito J, Matsuoka I. Inhibitory effect of betahistine on polysynap-tic neurons in the lateral vestibular nucleus. Arch Otorhinolaryngol 1982; 236: 229–36
   PubMedGoogle Scholar
• Matsuoka I, Ito J, Takahashi H, Sasa M, Takaori S. Experimental vestibular pharmacology: a minireview with special reference to neuroactive substances and antivertigo drugs. Acta Otolaryngol (Stockh) 1985; 62–70, Suppl 419
   Web of Science ®Google Scholar
• Horton BT. The clinical use of Beta-2-pyridylalkylamines. Part II. Treatment of histamine cephalgia (Hortons headache) with a note on angina pectoris. Proc Mayo Clin 1962; 37: 713–23
   PubMed Web of Science ®Google Scholar
• Elia JC. Dizziness. Presented as a scientific exhibit at the 114th annual convention of the American Medical Association. New York June, 1965
   Google Scholar
• Frew I JC, Menon GN. Betahistine hydrochloride in Menieres disease. Postgrad Med J 1976; 52: 501–3
   PubMed Web of Science ®Google Scholar
• Meyer J S, Mathew N T, Hartmann A, Rivera VM. Orally administered betahistine and regional cerebral blood flow in cerebrovascular disease. J Clin Pharmacol 1974; 14: 280
   PubMed Web of Science ®Google Scholar
• Rivera V M, Meyer J S, Baer P E, Faibisch G M, Mathew N T, Hartmann A. Vertebrobasilar arterial insufficiency with dementia. Controlled trials of treatment with betahistine hydrochloride. J Am Ger Soc 1974; 22: 397
   PubMed Web of Science ®Google Scholar
• Pathy J, Menon G, Reynolds A, Van Strik R. Betahistine hydrochloride (Serc) in cerebrovascular disease: a placebo-controlled study. Age Ageing 1977; 6: 179–84
   PubMedGoogle Scholar
• Canty P, Valentine J, Papworth S, Betahistine J. SJ. Betahistine in peripheral vertigo. A double-blind, placebo-controlled, cross-over study of Serc versus placebo. J Laryngol Otol 1981; 95: 687–92
   PubMed Web of Science ®Google Scholar
• Oosterveld WJ. Betahistine dihydrochloride in the treatment of vertigo of peripheral vestibular origin. A double-blind placebo-controlled study. J Laryngol Otol 1984; 98: 37–41
   PubMed Web of Science ®Google Scholar
• Fischer A JEM, van Elferen L WM. Betahistine in the treatment of paroxysmal attacks of vertigo. A double-blind investigation. JDR 1985; 10: 9
   Web of Science ®Google Scholar
• Legent F. Essai thérapeutique Serc versus placebo en double aveugle chez des patients souffrant de vertiges paroxystiques itératifs. Le Concours Medical ORL 1988; 29
   Google Scholar
• Oosterveld W F, Blijleven W, van Elferen L WM. Betahistine versus placebo in paroxysmal vertigo; a double-blind trial. JDR 1989; 14: 4
   Web of Science ®Google Scholar